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Abstract
This descriptive study investigates in a rabbit model of atherosclerosis (i) the extent of atherogenesis induced
by cyclosporine A (CsA) or hyperlipidemia alone or in combination and (ii) whether thymoquinone (TQ), a
known herbal antioxidant, offers protection against these effects. New Zealand White female rabbits were
assigned to five groups of six animals each: Group I, control; Group II, CsA [25 mg kg–1 day–1orally (PO)];
Group III, 1% cholesterol; Group IV, 1% cholesterol + CsA (25 mg kg–1 day–1 PO); and Group V, 1%
cholesterol + CsA (25 mg kg–1 day–1 PO) + TQ (10 mg kg–1 day–1 PO). Lipids and oxidative stress
parameters [Malondialdehyde (MDA) and protein carbonyl] and aortic atherosclerosis were compared. CsA
alone did not show a significant effect on either serum lipids and did not induce atherosclerosis. High-
cholesterol diet induced atherosclerosis (45 ± 11% of the intimal surface of aorta was covered with
atherosclerotic plaques). CsA and high-cholesterol diet increased atherosclerosis severity as measured from
intimal and media lesions, but did not affect the extent of atherosclerosis. TQ decreased aortic MDA by 83%.
It was also associated with reduced aortic atherosclerosis extend by 52% compared with Group IV. We
concluded that (i) CsA aggravates hyperlipidemia-induced atherosclerosis and (ii) TQ attenuates the
oxidative stress and atherogenesis induced by the combined effect of CsA and hyperlipidemia.
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Attenuated Combined Action of Cyclosporine A and Hyperlipidemia
on Atherogenesis in Rabbits by Thymoquinone
Ahmed Ragheb1,*, Ahmed Attia1,*, Fawzy Elbarbry2, Kailash Prasad3 and Ahmed Shoker1
1Department of Medicine, Royal University Hospital, University of Saskatchewan, Saskatoon, SK, Canada, 2School
of Pharmacy, Pacific University, Hillsboro, OR, USA and 3Department of Physiology, College of Medicine,
University of Saskatchewan, Saskatoon, SK, Canada
This descriptive study investigates in a rabbit model of atherosclerosis (i) the extent of athero-
genesis induced by cyclosporine A (CsA) or hyperlipidemia alone or in combination and (ii)
whether thymoquinone (TQ), a known herbal antioxidant, offers protection against these
effects. New Zealand White female rabbits were assigned to five groups of six animals each:
Group I, control; Group II, CsA [25mgkg–1 day–1 orally (PO)]; Group III, 1% cholesterol;
Group IV, 1% cholesterol+CsA (25mgkg–1 day–1 PO); and Group V, 1% cholesterol+CsA
(25mgkg–1 day–1 PO)+TQ (10mgkg–1 day–1 PO). Lipids and oxidative stress parameters
[Malondialdehyde (MDA) and protein carbonyl] and aortic atherosclerosis were compared.
CsA alone did not show a significant effect on either serum lipids and did not induce atheros-
clerosis. High-cholesterol diet induced atherosclerosis (45 11% of the intimal surface of aorta
was covered with atherosclerotic plaques). CsA and high-cholesterol diet increased atheroscler-
osis severity as measured from intimal and media lesions, but did not affect the extent of
atherosclerosis. TQ decreased aortic MDA by 83%. It was also associated with reduced
aortic atherosclerosis extend by 52% compared with Group IV. We concluded that (i) CsA
aggravates hyperlipidemia-induced atherosclerosis and (ii) TQ attenuates the oxidative stress
and atherogenesis induced by the combined effect of CsA and hyperlipidemia.
Keywords: atherosclerosis – cyclosporine A – hypercholesterolemia – reactive oxygen
species – rabbits – thymoquinone
Introduction
Patients receiving calcineurin inhibitors such as cyclos-
porine A (CsA) including transplant patients and those
with immune-mediated kidney diseases are usually hyper-
lipemic. Both of hyperlipidemia and CsA contribute to
the increased cardiovascular burden in humans and
animal models (1–3). Therefore, the relative contribution
of CsA versus hyperlipidemia alone or in combination to
the cardiovascular disease burden is difficult to dissect in
humans. Adding to this complexity is the fact that both
hyperlipidemia and CsA causes tissue injury by increasing
the oxidative stress. Furthermore, the effect of CsA on
atherosclerosis is complex. On one hand, CsA inhibits
T-cell function and thereby recruitment of inflammatory
cells needed to initiate atherosclerosis (4), which depends
on T-cell activation. On the other hand, CsA has been
demonstrated to synergistically exacerbate the vasocon-
strictive effects of oxidized low-density lipoprotein (5,6)
and thus aggravates atherosclerosis.
To determine the relative contribution of CsA and
hyperlipidemia to induce atherosclerosis, we reasoned
that high cholesterol-fed rabbits are a good model to
study. First, rabbits have been used reliably to induce
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an atheroma model with intact endothelium, which re-
sembles human atherosclerosis (7,8). Secondly, oxidative
stress has been linked to tissue injury by hyperlipidemia
(9,10). And thirdly, we have demonstrated that thymo-
quinone (TQ), which is the bioactive constituent of the
volatile oil of Nigella sativa seeds, protects against
hyperlipidemia-induced atherosclerosis in rabbits. This
effect is likely due to attenuation of oxidative stress
(11,12).
We therefore, wished to test the hypothesis that CsA
aggravates hyperlipidemia-induced atherosclerosis by syn-
ergistically enhancing the reactive oxygen species (ROS)
activity and that TQ ameliorates these effects. In this
study, we aimed to describe these effects.
Methods
Drugs
The drugs used were CsA A (CsA):Neoral oral solution
(100mgml1) (Novartis Pharmaceuticals Canada Inc.,
Dorval, QC, Canada) and TQ: 2-isopropyl-5-methyl-1,
4-benzoquinone (Sigma-Aldrich, St. Louis, MO, USA)
dissolved in pure corn oil (Sigma-Aldrich, St Louis,
MO 63103, USA) to give a concentration of 75mgml1.
Animals and Experimental Design
Thirty female New Zealand White rabbits, weighing 1.8–
2 kg and aged 6–8 weeks, were assigned to five groups of
six animals each (Table 1). After 1 week of adaptation on
regular diet. The rabbits were assigned to the following
groups: Group I, control; Group II, CsA (25mgkg–1 day–
1 per 8 weeks PO); Group III, 1% cholesterol; Group IV,
1% cholesterol+CsA (25mgkg–1 day–1 per 8 weeks PO);
and Group V, 1% cholesterol+CsA (25mgkg–1 day–1 8
weeks PO)+TQ (10mgkg–1 day–1 per 8 weeks PO). The
diet was prepared by Purina (St Louis, MO, USA) and
did not contain any antioxidants. Drugs were given orally
through nasogastric tubes (water was given ad libitum).
The rabbits were housed in individual cages at room tem-
perature of 22–24C and a relative humidity of 40–60%
under a 12-h light/12-h dark cycle. The experimental
protocols were approved by the Ethics Committee of
the University of Saskatchewan and the animal care
was performed according to the approved standards for
Laboratory Animal Care. Following 18 h of fasting,
blood samples (from the ear marginal artery) were
collected before (0 time) and after 4 and 8 weeks on
the respective diets for measurement of total cholesterol
(TC), triglycerides (TG), low density lipoprotein-
cholesterol (LDL-C), high density lipoprotein-cholesterol
(HDL-C), TC/HDL-C and serum malondialdehyde
(MDA). Serum protein carbonyl was measured at week
8 only. At the end of the protocol (8 weeks) rabbits
were anesthetized with ethanol, pentobarbital sodium
(50mgkg1 IV) (Bimeda-MTC Animal Health Inc.,
Cambridge, ON, Canada) in the marginal ear vein and
aortas were removed for the assessment of aortic MDA
and protein carbonyl and atherosclerotic changes.
Serum Lipids
TC, TG and HDL-C were measured on an automated
Beckman Synchron LX20 Clinical System Analyzer.
LDL-C was calculated. Cholesterol risk ratio was esti-
mated using the TC/HDL-C ratio.
Preparation of the Aortic Tissue for Measurement of
MDA and Protein Carbonyl
The aortic rings were cut at the roots of the aortic arches
and kept in buffered 10% formalin for histological exam-
ination using our previously described methods (9,13).
Aortas between the origin and bifurcation to iliac
arteries were removed, cleaned of gross adventitial
tissue and cut longitudinally into two halves. One half
was used for the assessment of atherosclerotic changes,
and the other half was kept on ice for preparation of the
supernatants, by a previously described method (14), for
measurement of the aortic tissue MDA and protein
carbonyl.
Serum and Aortic MDA (Thiobarbituric Acid-Reactive
Substances)
MDA levels in the aortic tissue supernatant and serum
were measured as thiobarbituric acid-reactive substances
(TBARs) by the previously described method (14,15). The
MDA content of the tissue was expressed as nmol mg1
proteins and that of serum as nmol ml1.
Serum Protein Carbonyl
The protein carbonyl levels in the serum were measured
using a Cayman Chemical Carbonyl Protein Assay Kit
(Cayman Chemical Company, Ann Arbor, Michigan,
USA). The absorbance was measured at a wavelength
between 360 and 386 nm using an ELx 808TM
Absorbance microplate reader (BioTek Instruments, Inc.
Highland Park, Vermont, USA). The protein carbonyl
Table 1. Experimental groups
Group Diet and drug regimen
I (n=6) Control; regular diet for 8 weeks
II (n=6) CsA; CsA [25mg kg–1 day–1 orally (PO)]
III (n=6) Cholesterol; 1% cholesterol diet for 8 weeks
IV (n=6) Cholesterol+CsA; 1% cholesterol+CsA
(25mg kg–1 day–1 PO)
V (n=6) Cholesterol+CsA+TQ; 1% cholesterol+CsA
(25mg kg–1 day–1 PO)+TQ (10mg kg–1 day–1 PO)
n=number.
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content of the tissue was expressed as nmol mg1 proteins
and that of serum as nmol ml1.
Tissue Protein Measurement
The protein content of was determined using a Modified
Lowry Protein Assay Kit (Pierce Biotechnology,
Rockford, IL, USA). The absorbance was measured at a
wavelength of 750 nm using an ELx 808TM Absorbance
microplate reader (BioTek Instruments, Inc., Highland
Park, Vermont, USA).
Assessment of Atherosclerotic Changes in the Aorta
The six animals from each group were assessed for ath-
erosclerotic changes using Herxheimer’s solution contain-
ing Sudan IV for lipid staining (9,16). Photographs of the
stained intimal surface of the aorta were taken with a
digital camera. The total and atherosclerotic areas of
the intimal surface of the aorta were measured by using
image analysis software Scion Image for Windows
(Scion Corporation, Frederick, MD USA). The extent
of atherosclerosis was expressed as a percentage of total
intimal surface area.
Quantification and Histological Assessment of
Atherosclerotic Lesions in the Aortic Rings
All methods are well established at our laboratory (9).
The aortic rings specimens were cut across and embedded
in paraffin. The histopathological findings were evaluated
by a blinded pathologist.
H&E, Verhoeff’s elastic stained sections were used for
microscopic morphometric evaluation using the Scion
software program. For these experiments, data have
been reported as the mean intimal area, determined by
six experimental measurements (17). Video microscopy
was used to outline the endothelium, internal elastic
lamina (IEL) and external elastic lamina (EEL). Then,
area measurements were calculated using an image soft-
ware program (Scion, Frederick, MD). Intima area
(between the endothelium and IEL) and media area
(between the IEL and EEL) were measured for each
aorta and averaged for each group.
The total cross-sectional intimal area was measured
between the endothelial cell monolayer and the internal
elastic lamina (IEL) and the total cross-sectional medial
area was measured between the external elastic lamina
(EEL) and the IEL as documented by previous methods
(18). The intimal and medial surface areas as well as the
intima/media ratio were taken as measures of the severity
of atherosclerosis (18).
Statistical Analysis
Results are expressed as mean SD. Repeated-measures
analysis of variance was used for statistical analysis. A
value of P<0.05 was considered significant.
Results
Body Weight
There was a progressive increase in the body weight of all
groups. No significant differences were observed between
the groups throughout the study period (data not shown).
Serum Lipids
The basal levels of serum TC in Groups I, II, III, IV and
V were 1.38 0.2, 1.35 0.3, 1.26 0.18, 1.35 0.3 and
1.42 0.4mmol l1, respectively. The basal levels were
not significantly different among the groups. The sequen-
tial changes in serum TC in the five groups are shown in
Fig. 1. The serum levels of TC remained unchanged in
Groups I and II while they were elevated in Groups III,
IV and V as compared to their basal levels. The levels at
week 8 were not different from those at week 4 in all
groups. In Group V, TC was significantly lower than
that for Groups III and IV at week 8.
Figure 1. Sequential changes in serum TC and TG in the five groups.
Results are expressed as meanSD. aP<0.05, 0 time versus 4 and 8
weeks in the respective groups. bP<0.05, Group I versus other groups.
cP<0.05, Group II versus Group III, IV or V. dP<0.05, Group III
versus Group IV or V. eP<0.05, Group IV versus Group V.
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The initial levels of serum TG in Groups I, II, III, IV
and V were 0.79 0.2, 0.94 0.5, 1.02 0.3, 0.74 0.3
and 0.85 0.2mmol l1, respectively. These initial levels
were not significantly different among the groups. The
sequential changes in serum TG in the five groups are
shown in Fig. 1. The serum levels of TG remained
unchanged in Groups I and II while they were elevated
in Groups III, IV and V as compared to their basal
levels. No significant differences were found between
the five groups at 4 and 8 weeks.
The basal levels of serum LDL-C in Groups I, II, III,
IV and V were 0.4 0.2, 0.49 0.2, 0.35 0.2, 0.43 0.1
and 0.51 0.4mmol l1, respectively. These levels were
not significantly different from each other. The sequential
changes in LDL-C in the five groups are shown in Fig. 1.
Serum levels of LDL-C remained unchanged in Groups I
and II while they were elevated in Groups III, IV and V
compared with their basal levels. No significant differ-
ences were found between the five groups at 4 and 8
weeks.
The initial levels of serum HDL-C in Groups I, II, III,
IV and V were 0.62 0.2, 0.51 0.4, 0.44 0.2, 0.58 0.1
and 0.52 0.1mmol l1, respectively. Again, these levels
were not significantly different among the groups. The
sequential changes in HDL-C in the five groups are
shown in Fig. 1. Serum levels of HDL-C remained
unchanged in Groups I and II while they were elevated
in Groups III, IV and V compared to their basal levels.
In Group V, HDL-C was significantly lower than that in
Groups III and IV at both 4 and 8 weeks.
The basal values of TC/HDL-C ratios in Groups I, II,
III, IV and V were 2.31 0.4, 2.64 0.8, 3.04 1,
2.35 0.3 and 2.75 0.5, respectively. The basal values
were not significantly different among the groups. The
sequential changes in these ratios in the five groups are
shown in Fig. 2. The ratios remained unchanged in
Groups I and II and increased in Groups III, IV and V
with respect to zero time. The risk ratio values were
increased in Groups III, IV and V as compared to
those in Groups I and II at 4 and 8 weeks. There were
no significant differences between Groups III, IV and V
at 8 weeks.
MDA Levels
Serum MDA
The basal values of serum MDA in Groups I–V were
0.93 0.4, 1.08 0.5, 0.84 0.3, 0.86 0.2 and
0.79 0.2 nmol l 1, respectively. The sequential changes
in serum MDA in the five groups are shown in Fig. 2.
The values remained unchanged in Group I but increased
in the other Groups at 4 and 8 weeks with respect to
baseline values. The increases in MDA levels in Groups
III and V were similar. MDA levels were the highest in
Group IV at 4 and 8 weeks.
Aortic Tissue MDA
The MDA contents of the aorta in the five groups are
shown in Table 2. In Group 1 it was 0.25 0.06 nmol
mg1 protein. In Groups II and III, the MDA levels
were similar but lower than that in Group IV.
Respectively MDA levels in Groups II, III and IV were
2.1-, 2.2- and 7.3-folds, respectively, higher as compared
with Group I. The MDA level in Group V was 83%
lower than that in Group III compared to Group IV,
while it was similar to that in Group I.
Serum Protein Carbonyl Levels
The serum protein carbonyl levels in the five groups
at 8 weeks are given in Table 2. Serum protein carbonyl
level in Group I was 1.34 0.25. The CsA and choles-
terol diet increased the serum protein carbonyl levels by
5.75- and 3.92-fold, respectively. The levels in Group IV
increased 11.33-fold as compared with Group I while the
levels were 2- and 2.9-fold higher as compared with
Groups II and III respectively. The serum protein
Figure 2. Sequential changes in serum LDL-C and HDL-C in the five
groups. Results are expressed as mean SD. aP<0.05, 0 time versus
4 and 8 weeks in the respective groups. bP<0.05, Group I versus other
groups. cP<0.05, Group II versus Group III, IV or V. dP<0.05, Group
III versus Group IV or V. eP<0.05, Group IV versus Group V.
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carbonyl levels were 38.8 % lower as compared to
Group IV.
Histological Effects
Extent of Atherosclerotic Plaque
Representative photographs of the atherosclerotic
changes in the intimal surface of the aortas from the
five groups are shown in Fig. 3 and the results are sum-
marized in Table 2. There were no atherosclerotic
changes in the intimal surface of the aortas in Groups I
and II. Significant areas of the intimal surfaces of Groups
III (45 11%), IV (38 4%) and V (18 8%) were
covered with atherosclerotic plaques. TQ administration
(Group V) reduced the development of cholesterol+
CsA-induced atherosclerosis by 52%.
Microscopic Changes in the Aortic Segments
Histological examination of all animals in each group
was first performed. Representative photographs of the
histological sections of the aorta stained with the H&E
stain and Verhoeff’s elastic stain from the five groups
were photographed and are shown in Figs 4, 5 and 6.
In the control group (Group I), specimens showed
normal arterial wall structure with no atherosclerotic
changes. Administration of CsA alone in Group II had
no effect on the atherosclerosis parameters tested. In
Group III moderate (30–60%) to severe (60%) athero-
sclerotic lesions was obvious. Administration of CsA with
the high-cholesterol diet in Group IV disclosed severe
diffuse atherosclerosis involving >85% of the arterial
wall and, in addition, smooth muscle cells proliferation
in the intima. Co-administration of TQ to CsA and the
high-cholesterol diet attenuated the vascular injury to
only minimal focal areas of atherosclerosis involving
<20% of the arterial wall. In addition there was no evi-
dence of smooth muscle cells proliferation.
Changes in the Intimal and Medial Thickness in the Aortic
Segments
Three parameters were compared; the intimal and medial
thickness of the aortic specimens as well as the intimal/
medial ratio. The results are summarized in Table 2. The
intimal and medial cross-sectional areas and the values of
intima/media ratio in Group I were 7.6 1.5 103 mm2,
52.3 9.7 103 mm2 and 0.15 0.01, respectively. CsA
Figure 3. Sequential changes in TC/HDL-C ratio and serum MDA in
the five groups. Results are expressed as mean SD. aP<0.05, 0 time
versus 4 and 8 weeks in the respective groups. bP<0.05, Group I ver-
sus other groups. cP<0.05, Group II versus Group III, IV or V.
dP<0.05, Group III versus Group IV or V. eP<0.05, Group IV
versus Group V.
Table 2. Aortic atherosclerotic changes and MDA and serum protein carbonyl levels in the five groups at 8 weeks
Group I
Control
Group II
CsA
Group III
Cholesterol
Group IV
Cholesterol+CsA
Group V
Cholesterol+CsA+TQ
Atherosclerosis
(% of total intimal surface)
0 0 45.08 11.65* 38.25 8.74*y 18.41 2.38*z§
Intimal area (103 mm2) 7.58 1.52 4.72 0.752 32.38 7.13* 58.48 15.51*z 14.82 1.87*z§
Medial area (103 mm2) 52.31 9.71 58.113 8.89 64.56 10.88 88.32 10.08*z 82.42 4.71z
Intima/media ratio 0.15 0.01 0.08 0.02 0.52 0.06* 0.65 0.12*z 0.18 0.03*z§
Aorta MDA (nmolmg1) 0.25 0.06 0.47 0.26* 0.53 0.32* 1.83 0.68*yz 0.30 0.03yz§
Serum protein carbonyl content
(nmolml1)
1.34 0.25 7.88 1.88* 5.34 1.36* 15.37 1.29*yz 9.50 1.74*yz§
Results are expressed as mean SD. Intimal and medial surface areas are expressed as 103 mm2.
*P<0.05, Group I versus other groups.
yP<0.05, Group II versus Groups III, IV and V.
zP<0.05, Group III versus Groups IV and V.
§P<0.05, Group IV versus Group V.
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alone did not exert any significant effect. In Group III,
the intimal cross-sectional area and the intima/media
ratio values were increased 4.3- and 3.5-fold, respectively,
compared to those in Group I. Administration of CsA to
the high-cholesterol diet, in Group IV, significantly
increased the intimal and medial cross-sectional areas
and the intima/media ratio 1.8, 1.4 and 1.3 times, respect-
ively, compared to that in Group III. Adding TQ in
Group V to both CsA- and cholesterol-rich diet
decreased the intimal cross-sectional area and the
intima/media ratio values by 73 and 72%, respectively,
compared to that in Group III.
Changes in the IEL and EEL in the Aortic Segments with
Verhoeff’s Elastic Stain
Administration of CsA only in Group II had no effect.
The high-cholesterol diet administration in Group III
produced diffuse damage to the IEL at the sites of the
atherosclerotic changes. Combining CsA to the high-
cholesterol diet disclosed diffuse damage to the IEL.
Co-administration of TQ to the CsA and the high-
cholesterol diet reduced the damage to minimal focal
areas of disruption in the IEL.
Discussion
This study highlights certain points for discussion; first,
there was no significant difference in the body weight
gain among the studied groups (data not shown) indicat-
ing that the various interventions did not affect the body
weight.
Figure 5. Representative photographs of the microscopic changes from the five groups stained with H&E stain. Note the normal arterial wall
structure in Group I, the increased intimal thickness in Group III that involves a large portion of the aortic circumference and almost the whole
circumference in Group IV. Also note the very small atheroma in Group V (magnification, 4).
Figure 4. Representative photographs of the intimal surfaces of aortas
from the five experimental groups showing Sudan IV-stained lipid
deposits. The brick-red lipid deposits in Groups III, IV and V.
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Second, our results corroborate similar effects of the
high-cholesterol diet on the lipid profile as reported in
previous studies (19,20).
This study demonstrates some of the biological effects
of clinical relevance, on CsA toxicity. First, CsA at the
dose used did not affect lipid levels and thus its effect on
the biochemical changes and tissue damage as reported in
Group II are not compounded by changes in serum lipid
levels. Among these biological effects this study corrob-
orates the increased oxidative state after CsA administra-
tion. This was well manifested by an increase in both
serum MDA and protein carbonyl levels by 1.4- and
5.8-fold, respectively, when compared to the control
group. In addition, CsA increased the aortic MDA level
1.9-fold, but this level of enhanced ROS activity was not
high enough to induce atherosclerosis. When CsA action
was compared to that induced by the high cholesterol
diet the results demonstrated a much higher level of oxi-
dative stress induced by the high cholesterol diet. The
combination of CsA and high cholesterol diet exerted a
synergistic effect on oxidative state as manifested by an
increase in serum MDA and protein carbonyl as well as
the aortic tissue MDA levels by 9.2-, 2- and 3.9-fold,
respectively, when compared to that in Group II (CsA
group) or when compared to the high cholesterol group
(1.3-, 2.9- and 2.3-fold, respectively).
Thus, the results proof the synergistic effect of CsA
and high cholesterol diet on increasing oxidative stress.
Other studies corroborated the deleterious combination
of hyperlipidemia and CsA on atherosclerosis (21).
We have recently demonstrated that TQ inhibits the
formation of atherosclerotic plaque in this model by
50% (12). In this current study, the addition of CsA fur-
ther enhanced the protective effect of TQ in the same
model by 80%. Taken together, the results raise the intri-
guing appeal that while TQ may abolish some of the
deleterious effects of combined administration of CsA
and hyperlipidemia, TQ spares also or even unmasks
some of the desirable effects of CsA such as the inhib-
ition of atherosclerosis. The anti-atherogenic effect of
CsA when used in combination with TQ is both intri-
guing and may have significant clinical relevance. First,
there is a plethora of evidence indicating a role for the
immune system in the development of vascular disease.
Thus, suppression of cell-mediated immunity by CsA
induced inhibition of T-lymphocytes (4,22–24).
In this study, we used other parameters to assess the
development of atherosclerosis; the intimal and medial
cross-sectional areas and the intima/media ratio. These
parameters were not tested in previous studies (4,7). A
main finding of this work was the beneficial effect of TQ
on atherogenesis parameters. First, it inhibited markers
of oxidative stress which included a decrease in the aortic
tissue MDA content by 84%. Another striking finding of
our work is the effect of TQ in this model. TQ in Group
V reduced the extent of atherosclerosis by half and
Figure 6. Representative photographs of the microscopic changes from the five groups stained with Verhoeff’s elastic stain with magnification 10 and
20. Note: (i)the normal arterial wall structure in Group I; (ii) the moderate to sever atherosclerosis in Group III that involves a large portion of the
aortic circumference; (iii) severe atherosclerosis in Group IV and the smooth muscle cells proliferation in the intima; (iv) also note the very small
atheroma in Group V and the absence of smooth muscle cells proliferation in the intima. Mild 30%, moderate=30–60%, severe 60%.
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induced 75% reductions in the intimal cross-sectional
area and the intima/media ratio as compared to CsA and
the high cholesterol diet in Group IV. Thus, these find-
ings establish the useful effect of TQ to attenuate athero-
genesis induced by hyperlipidemia which is aggravated
by CsA.
Our results differ from those obtained by Drew and
Tipping who studied the effect of CsA on a rabbit
model similar to ours (6). They used 1% cholesterol
diet for 4 weeks to induce atherosclerosis in
New Zealand white rabbits. CsA was given at a dose of
16mgkg1 of body weight IM every second day for
4 weeks. In their study they reported that CsA reduced
the atherosclerotic plaques development in the aortic
arch, the thoracic and abdominal aorta by 55, 68 and
86%, respectively. It also reduced the cross-sectional
plaque area in the aortic arch by 55%. They attributed
these effects to the anti-inflammatory effects of CsA
through the prevention of T-cells recruitment and reduc-
tion of foam cells accumulation in the atherosclerotic
plaques. It is possible that differences between our results
and theirs might be explained by the lower dose and the
shorter duration they used. This explanation is cor-
roborated with the results of Roselaar and co-workers
who described an atherogenic effect of a larger dose
CsA in the same animal model (4). This group induced
atherosclerosis by 0.5% cholesterol diet and gave CsA at
a higher dose (20 g kg1 subcutaneously daily for the first
week, and then twice weekly) for a longer dur-
ation (12 weeks). They reported that CsA increased the
extent of atherosclerosis in the aortic arch and the
thoracic aorta by 1.25- and 1.7-fold, respectively, as com-
pared to the high-cholesterol diet alone. From what is
said before we postulate that the effect of CsA on the ex-
tent of atherosclerotic plaques in cholesterol-fed animal
models may depend on the duration and the CsA dose.
When it is given in a low dose and for a short duration,
CsA may exert an anti-atherogenic effect while, a further
increase in the duration and dose induces atherogenesis.
Clinical relevance of these finding as shown in Fig 7
include the possible therapeutic use of TQ in hyperlipid-
emic patients on CsA therapy. Thus further controlled
studies in humans are suggested.
Limitations
Caution should be exercised to interpret our results. We
did not measure the oxidized LDL-C levels. Oxidation of
LDL-C molecules has been recognized as a major athero-
genic factor in post-transplant patients (25) and is con-
sidered a key factor in the biological processes that
trigger and accelerate atherosclerosis (26). Furthermore,
we neither measured tissue CsA levels nor tested the
effect of varying CsA dosing in our model. Currently
experiments are performed to address these limitations
and to delineate the underlying mechanisms of the bene-
ficial effects observed in this descriptive study.
Conclusion
Enhanced oxidative stress is blamed for both hyperlipid-
emia and CsA. In reality, most patients on CsA are also
hyperlipemic. Therefore, the contribution of CsA versus
hyperlipidemia-induced damage is difficult to dissect.
Similarly, in rabbits, hyperlipidemia has been reliably
shown to cause tissue injury due to enhanced oxidative
stress. Therefore, we raised the intriguing question to de-
termine the relevance of CsA to vascular injury in the
presence or absence of hyperlipidemia.
CsA administration alone induced oxidative stress but
did not induce significant effect on the serum lipids or the
development of atherosclerosis. However, the high-
cholesterol diet induced a significant increase in param-
eters of oxidative stress as well as serum levels of TC,
TG, LDL-C, HDL-C, the TC/HDL-C ratio. In addition,
it markedly enhanced atherogenesis. Thirdly, the addition
of CsA to high cholesterol diet led to a further amplifi-
cation in the oxidative stress and, thus, severe atherogen-
esis. A main finding of this study is that TQ significantly
attenuated aortic MDA levels and atherosclerosis in the
presence of the deleterious combination of CsA and
hyperlipidemia.
This study suggests TQ as a potential agent to protect
against the deleterious effect of combined CsA and
hyperlipidemia on atherosclerosis.
IMPROVE
ATHERO-
SCLEROSIS
Intima/ 
Media Ratio
Serum
Protein
Carbonyl
MDA
SERUM
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Figure 7. Hypothetical diagram to present the beneficial effect of
thymoquinone.
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